News

Debra Boyer, M.D., M.H.P.E., discussed the program of the 2024 American Thoracic Society International Conference in San Diego and the limits of artificial intelligence.

Set to launch this summer, Uber Caregiver is tailored specifically for caregivers and their loved ones, aiming to tackle challenges head on and enhance the overall care experience.

According to findings collected by Cedars-Sinai, artificial intelligence can reduce serious health risks associated with pregnancy and childbirth, and improve screening for some gynecological cancers.

But the waivers that allow for coverage of tele-health expire at the end the year. Several bills have been put forth to extend coverage.

The authors of an article about relatively low biosimilar use by people with inflammatory bowel disease have suggestions for how to mitigage the nocebo effect.

The efforts to prevent one disease increased another, likely due to the lack of methadone and sterile needles.

The Biotechnology Innovation Organization has some suggestions, including "platform designation" by FDA and changes at the CDC.

The FDA has approved six with dermatologic indications and more are in late-stage trials.

Home testing for fecal calprotectin, a commonly used marker in IBD diagnosis, and symptom quetionnaires might hasten the diagnosis of inflammatory bowel disease.

Enrollment has soared, but a relatively modest 2025 rate increase and changes to the Star rating system may lead plans to cut back on with their benefit offerings.

Crenolanib may have advantages over other therapies targeting acute myeloid leukemia with FLT3 gene mutations.

This month's episode of the Meet the Board podcast features a new member of our editorial advisory board, Marci J. Chodroff, MD, FACP, vice president of Medical Affairs at Magellan Rx Management, a Prime Therapeutics company.

Darzalex (daratumumab) is a monoclonal antibody drug currently approved for both refractory and new multiple myeloma. It’s available in intravenous and subcutaneous formulations.

Over the next five years, list prices of protected prescription drugs are expected grow between 1% and 4% a year, while net prices are expected to decline by the same amount, IQVIA predicts.

The splashy meeting with more than 7,000 people in attendance reflects the growth of the specialty pharmacy sector.

Although chronic respiratory diseases remain the third leading cause of mortality, they have received less attention from the global community.

Persisting stigma and COVID loneliness are partly to blame.

The FDA made several approvals this week, including converting Tivdak’s accelerated approval to full approval for cervical cancer and approvals for a high-concentration formulation of Cyltezo, Xolremdi for an ultra rare immune disorder and Libervant Film for epilepsy in young children.

Health plans that use Optum Rx as their pharmacy benefit manager (PBM) will be allowed to tier their coverage of GLP-1s and still receive rebates under an agreement the PBM has reached with the manufacturers, says the PBM president. Optum officials said later that the negotiations were still ongoing,

The University of Michigan National Poll on Healthy Aging recently conducted the survey focusing on the concerns of adults aged 50 and above regarding various health-related issues in their communities.

At 12 months, the rate of IBD-related surgeries for the monitored group was 1% versus 7% for the control group.

Rapidly progressing interstitial lung disease in anti-melanoma differentiation-associated gene 5 (MDA5) antibody-positive dermatomyositis (DM) is known for its high death rate because it worsens quickly and causes breathing difficulties within three months of initial lung symptoms. However, there isn't much information about the timing between the diagnosis of ILD and MDA5 antibody-positive DM because most research focuses on either the frequency or the death rates rather than the timing of onset.

The retired four-start Navy admiral shared lessons learned from his training as a Navy SEAL and other parts of his life in his keynote address.

Cost and lack of access were two of the most common reasons given in new survey.

Optum and Takeda executives discuss their efforts to collaborate on implementing a value-based care for people with inflammatory bowel disease.

Company officials said a challenging reimbursement environment and escalating operating costs created a lack of profitability for the business.

In a discussion with Managed Healthcare Executive, Cate Lockhart, Pharm.D., Ph.D., executive director, Biologics and Biosimilars Collective Intelligence Consortium, talks about the disappointment surrounding the uptake of Humira biosimilars.

In a discussion with Managed Healthcare Executive, Cate Lockhart, Pharm.D., Ph.D., executive director, Biologics and Biosimilars Collective Intelligence Consortium, talks about whether or not she favors ending interchangeability designation for biosimilars.